BioCatalystWatch
HINDWorkspace / HIND / OverviewCompany library
Price
Market cap
Next catalystExpected 2H 2026VT1908 · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

DNA gyrase × topoisomerase IV × MD2-TLR interaction

PreINDP1P2FilingApproved
Upcoming / outlook

VT1908

IMPDH2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

VT1908

IMPDH2

PreINDP1P2P3FilingApproved
Upcoming / outlook

DNA gyrase × topoisomerase IV × MD2-TLR interaction

PreINDP1P2FilingApproved
Upcoming / outlook

Other pipelines

VB-1953

DNA gyrase × topoisomerase IV × MD2-TLR interaction

VB-1953

DNA gyrase × topoisomerase IV × MD2-TLR interaction

Partner / License out

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

HIND PR & News

PR & News

HIND SEC archive